Regardless of remarkable effects demonstrated in GBM cell lines in vitro, ICB therapies based on targeting PD-1, PD-L1, and CTLA4 have failed to improve patient survival in clinical trials, possibly in part due to the strong heterogeneity and immune evasion characteristic of GBM [6]. This evidence concerns the gene CD274 and glioblastoma.